11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Numerous factors contribute to uncertainty in test measurement procedures, and this uncertainty can have a significant impact on the downstream clinical utility and cost-effectiveness of testing strategies. Currently, however, there is no clear guidance concerning if or how such factors should be considered within Health Technology Assessments (HTAs) of tests.

          Objective

          The aim was to provide an introduction to key concepts in measurement uncertainty for the HTA community and to explore, via systematic review, current methods utilised within HTAs.

          Methods

          HTAs of in vitro tests including a model-based economic evaluation were identified via the Centre for Reviews and Dissemination (CRD) HTA database and key reimbursement authority websites. Data were extracted to explore the specific components of measurement uncertainty assessed and methods utilised. The findings were narratively synthesised.

          Results

          Of 107 identified HTAs, 20 (19%) attempted to assess components of measurement uncertainty: 15 did so via some form of pre-model assessment (such as a literature review or laboratory survey); four also included components within the economic model; and one considered measurement uncertainty within the model only. One study quantified the impact of measurement uncertainty on cost-effectiveness and found that this parameter significantly changed the results, but did not impact the overall decision uncertainty.

          Conclusion

          A minority of HTAs identified from this review used various approaches to assess and/or incorporate the impact of measurement uncertainty, indicating that these assessments are feasible. Uncertainty remains around best practice methodology for conducting such analyses; further research is required to ensure that future HTAs are fit for purpose.

          Electronic supplementary material

          The online version of this article (10.1007/s40273-018-0638-1) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

          There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that repeat biopsies may be necessary to obtain a diagnosis. The PROGENSA(®) prostate cancer antigen 3 (PCA3) assay (Hologic Gen-Probe, Marlborough, MA, USA) and the Prostate Health Index (phi; Beckman Coulter Inc., Brea, CA, USA) are two new tests (a urine test and a blood test, respectively) that are designed to be used to help clinicians decide whether or not to recommend a repeat biopsy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            A standardized framework for the validation and verification of clinical molecular genetic tests

            The validation and verification of laboratory methods and procedures before their use in clinical testing is essential for providing a safe and useful service to clinicians and patients. This paper outlines the principles of validation and verification in the context of clinical human molecular genetic testing. We describe implementation processes, types of tests and their key validation components, and suggest some relevant statistical approaches that can be used by individual laboratories to ensure that tests are conducted to defined standards.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              History of HTA: Introduction.

                Bookmark

                Author and article information

                Contributors
                0131 343 30847 , a.f.c.smith@leeds.ac.uk
                Journal
                Pharmacoeconomics
                Pharmacoeconomics
                Pharmacoeconomics
                Springer International Publishing (Cham )
                1170-7690
                1179-2027
                3 March 2018
                3 March 2018
                2018
                : 36
                : 7
                : 823-835
                Affiliations
                [1 ]ISNI 0000 0004 1936 8403, GRID grid.9909.9, Academic Unit of Health Economics, , Leeds Institute of Health Sciences, University of Leeds, ; Leeds, UK
                [2 ]ISNI 0000 0001 2116 3923, GRID grid.451056.3, National Institute of Health Research (NIHR) Leeds In Vitro Diagnostic Co-operative (IVDC), ; Leeds, UK
                [3 ]ISNI 0000 0004 1936 8403, GRID grid.9909.9, Leeds Centre for Personalised Medicine and Health, , University of Leeds, ; Leeds, UK
                [4 ]ISNI 0000 0004 1936 7988, GRID grid.4305.2, Edinburgh Cancer Research Centre, , University of Edinburgh, ; Edinburgh, UK
                Article
                638
                10.1007/s40273-018-0638-1
                5999143
                29502176
                55413b28-bfca-4f06-8baf-4b80258b901f
                © The Author(s) 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000659, Research Trainees Coordinating Centre;
                Award ID: DRF-2016-09-084
                Award Recipient :
                Categories
                Systematic Review
                Custom metadata
                © Springer International Publishing AG, part of Springer Nature 2018

                Economics of health & social care
                Economics of health & social care

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content86

                Most referenced authors141